MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Phase 1DA-1726Positive

AI Analysis

Summary

MetaVia reported Q2 2026 financial results and announced that all active patients in its Phase 1 Part 3 study of DA-1726 successfully reached the highest planned dose levels of 48 mg and 64 mg, with 16-week topline data expected in Q4 2026.

Clinical Trial Data

Phase

Phase 1 Part 3

Outcome Details

All active patients successfully reached highest planned dose levels of 48 mg and 64 mg

Importance:5/10

Sentiment:

0.60

Phase 1dose escalationtopline dataQ4 2026 readout

Related Companies

$MTVA

Read the original article

Published by PR Newswire Biotech on August 6, 2026 8:05 PM

Read Original